Bayer Launches OTC Product With Extended-Release Technology Developed By Andrx.

Business Editors

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Aug. 31, 2000

ANDRX CORPORATION (Nasdaq:ADRX) today announced that Bayer Corporation's Consumer Care Division has launched Aleve Cold and Sinus medication utilizing extended-release technology developed by Andrx. The Aleve Cold and Sinus product combines Andrx's drug delivery technology with Bayer's technology and provides up to 12 hours of relief from pain and nasal congestion with a single one-caplet dose. Bayer has received three years of marketing exclusivity for this product from the U.S. Food and Drug Administration, ending November 29, 2002. Beginning mid-September, Bayer plans to spend approximately $20 million to advertise and market the benefits of this product.

Andrx President, Elliot F. Hahn, Ph.D., said, "While branded and generic controlled-release products are the primary applications for Andrx's drug delivery technologies, we are excited because this is the first OTC product in the marketplace that incorporates our technology. We are also very pleased that Bayer has decided to promote this product and its benefits with a marketing campaign timed for this year's cold and flu season."

Andrx is engaged in the formulation and commercialization of oral controlled-release pharmaceuticals utilizing its proprietary drug delivery technologies. In its ANDA program, the Company is developing generic versions of selected high sales volume controlled-release brand name pharmaceuticals. In its NDA program, the Company is developing its own brand name formulations of certain existing drugs that it believes may be improved by the application of the Company's drug delivery technologies. The Company also markets and distributes pharmaceutical products manufactured by third parties and, through its Cybear, Inc. subsidiary (Nasdaq:CYBA), is developing internet-based software and applications for the healthcare industry.

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this report that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "expect", "believe", "anticipate", "intend", "could", "would", "estimate", or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, including those risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission.